TIM-3: Galectin-9: A Novel Regulatory Pathway of Alloimmune Activation
TIM-3:Galectin-9:同种免疫激活的新型调控途径
基本信息
- 批准号:8312994
- 负责人:
- 金额:$ 31.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-15 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAffectAlloantigenAllograft ToleranceAllograftingAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntibody FormationAntigen PresentationAntigensApoptosisApoptoticAreaAscaridilB cell differentiationB-LymphocytesBehaviorBindingCD28 geneCD4 Positive T LymphocytesCTLA4-IgCardiacCell DeathCell Differentiation processCell modelCell physiologyCellsChronicClinical ProtocolsCollaborationsCommitDataDevelopmentEndothelial CellsEquilibriumFrequenciesFunctional disorderGalactose Binding LectinGalectin 3GenerationsGoalsHelper-Inducer T-LymphocyteHumanImmuneImmunityImmunosuppressionIn VitroInflammatory ResponseInterleukin-6InvestigationLaboratoriesLifeLigandsMHC antigenMaintenanceMediatingMemoryModelingMolecularMolecular Mechanisms of ActionMorbidity - disease rateMusMyocardialNatural ImmunityNatureNecrosisOrganOrgan TransplantationPathway interactionsPatientsPhenotypePlayProceduresProductionPublishingRecombinantsRegulationRegulatory PathwayRegulatory T-LymphocyteResearchResistanceRoleSignal TransductionSolidSurfaceT cell differentiationT cell responseT memory cellT-LymphocyteTestingTransgenic AnimalsTranslatingTransplantationVirus Diseasesactivating transcription factor 3adaptive immunityallograft rejectionanergybaseclinically significantcytokineend-stage organ failureexhaustionheart allograftimprovedin vivoisoimmunitymemory recallmouse modelnovelnovel strategiespreventreceptorresearch studyresponsetooltranscription factor
项目摘要
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells.
- DOI:10.1111/j.1600-6143.2012.04180.x
- 发表时间:2012-10
- 期刊:
- 影响因子:0
- 作者:Magee CN;Boenisch O;Najafian N
- 通讯作者:Najafian N
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NADER NAJAFIAN其他文献
NADER NAJAFIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NADER NAJAFIAN', 18)}}的其他基金
TIM molecules and the innate: adaptive interface in alloimmunity
TIM 分子和先天性:同种免疫中的适应性界面
- 批准号:
8707632 - 财政年份:2013
- 资助金额:
$ 31.2万 - 项目类别:
Negative Costimulatory Pathways in Rejection & Tolerance
排斥反应中的负性共刺激途径
- 批准号:
7433308 - 财政年份:2007
- 资助金额:
$ 31.2万 - 项目类别:
Negative Costimulatory Pathways in Rejection & Tolerance
排斥反应中的负性共刺激途径
- 批准号:
7263396 - 财政年份:2007
- 资助金额:
$ 31.2万 - 项目类别:
Negative Costimulatory Pathways in Rejection & Tolerance
排斥反应中的负性共刺激途径
- 批准号:
7629565 - 财政年份:2007
- 资助金额:
$ 31.2万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 31.2万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 31.2万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 31.2万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 31.2万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 31.2万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 31.2万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 31.2万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 31.2万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 31.2万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 31.2万 - 项目类别:














{{item.name}}会员




